MARKETS / BALCAO / SCND
BALCAO · LABORATORY ANALYTICAL INSTRUMENTS · SMALL CAP

Scientific Industries, Inc. SCND

15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$5.1M
▲ 5.4% vs FY2024
EPS · FY25
$-0.11
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-12.3%
Net margin · FY25
-24.1%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 5.1M
Revenue, FY2025 · full 15-year series below
Revenue Net income
0.0040.0080.0120.0-0.0201020132016201920232025
0.0040.0080.0120.0-0.02016201920232025

The company lost 24 cents on every revenue dollar this year.

Per share
USD -0.11
Diluted EPS, FY2025
EPS
0.40.81.2-0.11201020132016201920232025
0.40.81.2-0.112016201920232025

The company pays no cash dividend.

Profitability
-12.3%
Return on equity, FY2025
ROE
4812-12.3%201020132016201920232025
4812-12.3%2016201920232025
Operating margin-156.1%
Net margin-24.1%
Return on assets-10.1%

Each USD of equity lost 12 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
−12.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−12.4%
−6.2%
−1.0%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.01B
Shares outstanding, FY2025
0.000.01201020132016201920232025
0.000.012016201920232025
Change, 5 years+84.7%
Change, 10 years

The share count grew 85% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 12.6M
total assets, end of FY2025
Total assetsUSD 12.6M
EquityUSD 10.7M
CashUSD 955,000.00
Current ratio7.70×

Equity funds 85% of total assets.

History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
0.0
−0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
EPS, diluted $
−0.11
−0.61
−1.27
·
−1.00
−0.46
0.43
−0.11
−0.05
0.11
0.01
−0.05
0.30
0.05
0.19
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
90
47
ROE %
−12.3
−56.0
−65.4
−62.5
−19.4
−7.8
10.7
−2.8
−1.2
2.8
0.2
−1.4
7.6
1.4
4.9
Shares out B
0.01
0.01
0.01
0.01
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
·
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
58 of 59
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 1 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed